Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Liver Cirrhosis-Pipeline Review, H1 2015

Liver Cirrhosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Liver Cirrhosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Liver Cirrhosis-Pipeline Review, H1 2015', provides an overview of the Liver Cirrhosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liver Cirrhosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liver Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liver Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Liver Cirrhosis Overview 8

Therapeutics Development 9

Pipeline Products for Liver Cirrhosis-Overview 9

Pipeline Products for Liver Cirrhosis-Comparative Analysis 10

Liver Cirrhosis-Therapeutics under Development by Companies 11

Liver Cirrhosis-Therapeutics under Investigation by Universities/Institutes 13

Liver Cirrhosis-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Liver Cirrhosis-Products under Development by Companies 17

Liver Cirrhosis-Products under Investigation by Universities/Institutes 19

Liver Cirrhosis-Companies Involved in Therapeutics Development 20

Alfa Wassermann S.p.A 20

Conatus Pharmaceuticals Inc. 21

Digna Biotech, S.L. 22

Galectin Therapeutics, Inc. 23

Gilead Sciences, Inc. 24

GNI Group Ltd. 25

Pacific Therapeutics Ltd. 26

PharmaIN Corporation 27

Pharmicell Co., Ltd. 28

S-Evans Biosciences, Inc. 29

Stelic Institute & Co. 30

Stempeutics Research Private Limited 31

Liver Cirrhosis-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Combination Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

(sofosbuvir + GS-5816)-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Cell Therapy for Liver Cirrhosis-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

DB-027-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DB-036-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

emricasan-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

F-351-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GR-MD-01-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

GR-MD-02-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

GXHPC-1-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Livercellgram-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Monoclonal Antibodies to Antagonize Transforming Growth Factor Beta 1 for HCV associated Liver Cirrhosis-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

PTL-303-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Px-104-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

rifaximin-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

simtuzumab-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Stem Cell Therapy for Liver Cirrhosis-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Stem Cell Therapy for Liver Cirrhosis-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Stempeucel-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

STNM-04-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

thrombopoietin-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Undisclosed Peptide for Liver Cirrhosis-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Liver Cirrhosis-Recent Pipeline Updates 74

Liver Cirrhosis-Dormant Projects 88

Liver Cirrhosis-Discontinued Products 89

Liver Cirrhosis-Product Development Milestones 90

Featured News & Press Releases 90

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 90

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 91

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 92

Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 93

Jan 20, 2011: Stempeutics Research's Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis 94

Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease 94

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

Number of Products under Development for Liver Cirrhosis, H1 2015 9

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Liver Cirrhosis-Pipeline by Alfa Wassermann S.p.A, H1 2015 20

Liver Cirrhosis-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 21

Liver Cirrhosis-Pipeline by Digna Biotech, S.L., H1 2015 22

Liver Cirrhosis-Pipeline by Galectin Therapeutics, Inc., H1 2015 23

Liver Cirrhosis-Pipeline by Gilead Sciences, Inc., H1 2015 24

Liver Cirrhosis-Pipeline by GNI Group Ltd., H1 2015 25

Liver Cirrhosis-Pipeline by Pacific Therapeutics Ltd., H1 2015 26

Liver Cirrhosis-Pipeline by PharmaIN Corporation, H1 2015 27

Liver Cirrhosis-Pipeline by Pharmicell Co., Ltd., H1 2015 28

Liver Cirrhosis-Pipeline by S-Evans Biosciences, Inc., H1 2015 29

Liver Cirrhosis-Pipeline by Stelic Institute & Co., H1 2015 30

Liver Cirrhosis-Pipeline by Stempeutics Research Private Limited, H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Assessment by Combination Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Mechanism of Action, H1 2015 37

Number of Products by Stage and Route of Administration, H1 2015 39

Number of Products by Stage and Molecule Type, H1 2015 41

Liver Cirrhosis Therapeutics-Recent Pipeline Updates, H1 2015 74

Liver Cirrhosis-Dormant Projects, H1 2015 88

Liver Cirrhosis-Discontinued Products, H1 2015 89

List of Figures

Number of Products under Development for Liver Cirrhosis, H1 2015 9

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Top 10 Routes of Administration, H1 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 39

Number of Products by Top 10 Molecule Types, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alfa Wassermann S.p.A

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

GNI Group Ltd.

Pacific Therapeutics Ltd.

PharmaIN Corporation

Pharmicell Co., Ltd.

S-Evans Biosciences, Inc.

Stelic Institute & Co.

Stempeutics Research Private Limited

Liver Cirrhosis Therapeutic Products under Development, Key Players in Liver Cirrhosis Therapeutics, Liver Cirrhosis Pipeline Overview, Liver Cirrhosis Pipeline, Liver Cirrhosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com